Trastuzumab for Gastric Cancer: 8 Real Stories

Gastric cancer surgery and adjuvant treatment followed by endocrine complications

Patient Info: Anonymized, Female, 40s

After cancer treatment, she was hospitalized with severe nutritional and endocrine complications and improved with hormone replacement and nutritional support.

PubMed CentralRead more →

Stage IV HER2-Positive Gastric Cancer With Immune Thrombocytopenia During Treatment

Patient Info: Anonymized | Stage IV

Biomarkers: HER2 amplified; PD-L1 CPS 10; pMMR; Claudin18.2 overexpression

Metastatic Site: liver, omentum

CT in March 2024 showed progression with enlarging gastric and omental lymphadenopathy and new liver metastases.

PubMed CentralRead more →

HER2-Positive Metastatic Stomach Cancer Presenting With Tumor Lysis Syndrome

Patient Info: Anonymized, Male | Stage Metastatic/Advanced

Biomarkers: HER2 positive

Metastatic Site: liver

His metastatic gastric cancer progressed despite FOLFOX6 and trastuzumab. He entered hospice about 1 year later and died a few months afterward.

PubMed CentralRead more →

HER2-positive metastatic gastric cancer responding to trastuzumab deruxtecan rechallenge

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

After trastuzumab deruxtecan was restarted, his symptoms improved after the first cycle and imaging showed tumor shrinkage after 3 cycles. He was still receiving treatment without progression at the latest follow-up.

PubMed CentralRead more →

Stage IV HER2-Positive Gastric Cancer: Bryan's Patient Story

Patient Info: Bryan Chagolla, Male, Under 40 | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver

Bryan had a strong response to trastuzumab deruxtecan in 2021. He died on May 13, 2022, surrounded by loved ones.

Stage IV gastric cancer with low platelets managed so chemotherapy could continue — Case 2

Patient Info: Anonymized, female, 70+ | Stage IV

After partial splenic embolization, her platelet count recovered and thrombocytopenia did not recur. She was receiving second-line ramucirumab plus paclitaxel at the latest follow-up.

PubMed CentralRead more →

Sjögren syndrome during nivolumab treatment for HER2-positive metastatic gastric cancer

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, lungs, adrenal gland

One year after nivolumab was stopped, the shrinkage of lung metastases was maintained and the adrenal metastasis remained unchanged, although severe dry-mouth symptoms from treatment-related Sjögren syndrome persisted.

PubMed CentralRead more →

Graves disease during nivolumab treatment for HER2-positive metastatic gastric cancer

Patient Info: Anonymized, male, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, brain

After progression through several treatment lines and development of brain metastasis, he died 4 months after evaluation for nivolumab-associated Graves disease, more than 1.5 years after his Stage IV gastric-cancer diagnosis.

PubMed CentralRead more →